Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy ; volume:19 ; number:1 ; day:11 ; month:2 ; year:2019 ; pages:1-12 ; date:12.2019
BMC cancer ; 19, Heft 1 (11.2.2019), 1-12, 12.2019
- Creator
-
Al-Salam, Suhail
Sudhadevi, Manjusha
Awwad, Aktham
Al Bashir, Mohamed
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5316-y
- URN
-
urn:nbn:de:101:1-2019031321571900766058
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Al-Salam, Suhail
- Sudhadevi, Manjusha
- Awwad, Aktham
- Al Bashir, Mohamed
- SpringerLink (Online service)
Other Objects (12)
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy